BioHarvest FAQ

BioHarvest Sciences is a publicly listed company, listed on the Nasdaq Global Market under the symbol “BHST”.

In Europe, BioHarvest trades on the Deutsche Boerse Frankfurt Exchange under the symbol “8MV”  

All common shares purchased in either of these markets are for the same public shares of Bioharvest.

As an early-stage biotechnology company, additional financings may be undertaken to fund expansion and development.  

All investor-related questions are welcome, and we will respond within 24 hours. Contact our Investor Relations team at info@bioharvest.com.  

Yes, it can. In February 2024, Bioharvest announced the launch of the new Contract Development and Manufacturing Organization (CDMO) Services business unit. This business unit allows pharmaceutical, cosmeceutical, nutraceutical and nutrition industry leaders the opportunity to partner with BioHarvest to utilize its Botanical Synthesis Process technology through a typical CDMO contracting model. This proprietary process technology enables the development and manufacturing of patentable plant based compounds. 

For more information on CDMO Services, please contact info@bioharvest.com.

Botanical Synthesis is non-GMO. Here is an overview of the process in 4 steps:

1. We take the Plant – We first select the desired plant that contains important active phytochemicals and then our research teams identify the most prolific cells generating the targeted compounds.

2. Cell Research – Selected cells are cultured in nutrient-packed Petri dishes, where A.I. assisted experiments are conducted to mirror the cell’s natural growth cycles within the original plant, and to magnify the concentrations of the targeted compounds. When the targeted compounds have been successfully mirrored and magnified, the optimized plant cells now constitute the “cell bank” that will be used for perpetual production. At this stage we have total independence of the mother plant and we will never use it again!

3. Production – BioHarvest is the only company to have successfully achieved industrial-scale production of complex plant cells in liquid media. Through our Botanical Synthesis process, we are now able to “train” the mirrored cells in our perpetual cell bank to grow in 1000L + sized bioreactors. Within 3 weeks, (17 cycles per year), the cells grow to reach optimal yield and adequate biomass. The Botanical Synthesis process is conducted in aseptic conditions and in total compliance with all ISO and GMP requirements.

4. Bio Harvesting – When the “multiplied” plant cells have reached optimal yield, the liquid media is removed, and the cells are dried. In the case of our nutraceutical products, such as VINIA or our future Olive cell product, that dried powder is then encapsulated, with no further processing. This perpetual cycle is repeated, producing clean and fingerprint-consistent crops for every harvest, never going back to the plant again.

There is no genetic modification of plant cells.

If you have any questions about our technology or commercialization plans, contact us at info@bioharvest.com.  All queries will be answered within 24 hours.  

For Investor information, Click on our “Investors” tab, or visit our Investor Relations microsite at  https://ir.bioharvest.com.

If you are an investor who would like to join an informal Q+A Zoom call with a small group of other investors and CEO Ilan Sobel, we host a Zoom “Coffee With Ilan” Q+A weekly, at 11am PST each Wednesday PST. Contact info@bioharvest.com to book your spot in an upcoming session.  

Subscribe to our social media channels for a steady stream of corporate information, or subscribe to our News Alert list to receive our biggest news updates directly from us.  

We strive to be as transparent and communicative as is possible for a public company. BioHarvest hosts interactive shareholder webinars quarterly, and we welcome all comments and questions from our shareholder partners as we push forward on our mission to develop plant-based compounds that will improve human wellness while preserving the planet for generations to come. 

The Botanical Synthesis technology platform is capable of growing any type of plant cells. We prioritize our products in order to optimize both Human Utility Value and shareholder return. Our current product pipeline is focused on grape, olive, and pomegranate formulations. While our Research and Development team is actively reviewing other cell types, our current focus on near term profitability is to prioritize the development of products that include VINIA.

The “VINIA Inside” product lines now include Hot Beverages, which are multiple varieties of Superfood coffees (featuring Premium Medium roast and decaffeinated roast), teas (Cranberry Hibiscus Herbal, Premium Matcha Green Tea, our Signature Fine Cut Green Tea, and the classic English Breakfast Black tea), and VINIA 2X Daily Chews, which were launched in June 2025.

 The future product development pipeline includes additional Hot Beverage products such as Nespresso compatible pods and teas, a performance hydration product, and skin formulations. 

For full details on VINIA products, please visit https://vinia.com

We are actively testing new horizons for our Red Grape Cells, olive cells, and pomegranate cells unique compositions and these are expected to produce new options for future products.  

The Olive cell product is proceeding through testing and regulatory stages, and is expected to be released in 2026.